AlloVir stockholders elect three Class I directors and ratify Deloitte as auditor at 2024 annual meeting

Kalaris Therapeutics, Inc.

Elected Juan Vera (77.7M for, 4.2M withhold), Morana Jovan-Embiricos (76.2M for, 5.8M withhold), Derek Adams (76.2M for, 5.7M withhold) as Class I directors.
Ratified Deloitte & Touche as independent auditor for FY2024: 104.2M for, 276K against, 400K abstain.
Broker non-votes totaled 22,994,115 on each director election; no other matters voted on.
Meeting held June 6, 2024; record date April 15, 2024 with 114,912,515 shares outstanding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.